search
Back to results

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Primary Purpose

Acne Vulgaris

Status
Completed
Phase
Phase 1
Locations
Mexico
Study Type
Interventional
Intervention
Isotretinoin: Reference Medication 1
Isotretinoin: Reference Medication 2
Isotretinoin: Test Medication
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris focused on measuring capsule, Isotretinoin, Bioequivalence

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Included in study will be male volunteers.
  • Ages between 18 and 45 years old.
  • BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2).
  • Anti-doping tests negative results.
  • Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B surface antigen), and rapid plasma regain (RPR; syphilis test).
  • Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values.
  • Normal Electrocardiogram (ECG) and Chest X-rays.
  • Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and after each dosification period.
  • Obtain a grade of zero in the C-SSRS.
  • Signed the Informed Consent corresponding to the bioequivalence study.
  • In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant".

Exclusion Criteria:

  • Electrocardiographic Anomalies; radiological
  • Anti-doping tests positive results,
  • Positive results regarding RPR; HIV and HBsAg tests.
  • Personal or family history of allergy to medication in question.
  • Having any kind of allergy, since these persons are in higher risk of suffering from medication allergy.
  • Tobacco use.
  • Persons undergoing any medical treatment.
  • Existence of concurrent or intercurrent disease.
  • History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia).
  • Existence of justified doubt regarding questionnaire answers truthfulness.
  • Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study.
  • Presence of clinically important gastrointestinal diseases or malabsorption history during the last year.
  • Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption.
  • Drugs or alcohol addiction history requiring treatment.
  • Refuse to take the scale 'C-SSRS, before and after each dosification period.
  • Obtain a grade greater than zero in the C-SSRS.
  • Do not sign the Informed Consent corresponding to the bioequivalence study.
  • Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998.

Sites / Locations

  • GSK Investigational Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Isotretinoin Arm

Arm Description

All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.

Outcomes

Primary Outcome Measures

Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t)
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity)
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Maximum drug concentration (Cmax)
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Time to maximum drug concentration (Tmax)
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.

Secondary Outcome Measures

Full Information

First Posted
May 16, 2013
Last Updated
June 9, 2017
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT02498288
Brief Title
A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition
Official Title
Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
May 31, 2013 (Actual)
Primary Completion Date
July 15, 2013 (Actual)
Study Completion Date
July 15, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, crossover, randomized, single dose, three treatments, three periods and six sequences, single dosage, balanced study to determine Bioequivalence of Isotretinoin. Bioequivalence will be compared between the reference medication one (T1) vs the test medication (T3): (T1 vs T3); and the reference medication two (T2), vs test medication (T3): (T2 vs T3). Finally, treatments T1 vs T2 will be compared statistically to determine if they are bioequivalent.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
capsule, Isotretinoin, Bioequivalence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Isotretinoin Arm
Arm Type
Experimental
Arm Description
All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
Intervention Type
Drug
Intervention Name(s)
Isotretinoin: Reference Medication 1
Intervention Description
Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Intervention Type
Drug
Intervention Name(s)
Isotretinoin: Reference Medication 2
Intervention Description
Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Intervention Type
Drug
Intervention Name(s)
Isotretinoin: Test Medication
Intervention Description
Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
Primary Outcome Measure Information:
Title
Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t)
Description
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Time Frame
Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Title
Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity)
Description
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Time Frame
Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Title
Maximum drug concentration (Cmax)
Description
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Time Frame
Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Title
Time to maximum drug concentration (Tmax)
Description
Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.
Time Frame
Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Included in study will be male volunteers. Ages between 18 and 45 years old. BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2). Anti-doping tests negative results. Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B surface antigen), and rapid plasma regain (RPR; syphilis test). Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values. Normal Electrocardiogram (ECG) and Chest X-rays. Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and after each dosification period. Obtain a grade of zero in the C-SSRS. Signed the Informed Consent corresponding to the bioequivalence study. In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant". Exclusion Criteria: Electrocardiographic Anomalies; radiological Anti-doping tests positive results, Positive results regarding RPR; HIV and HBsAg tests. Personal or family history of allergy to medication in question. Having any kind of allergy, since these persons are in higher risk of suffering from medication allergy. Tobacco use. Persons undergoing any medical treatment. Existence of concurrent or intercurrent disease. History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia). Existence of justified doubt regarding questionnaire answers truthfulness. Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study. Presence of clinically important gastrointestinal diseases or malabsorption history during the last year. Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption. Drugs or alcohol addiction history requiring treatment. Refuse to take the scale 'C-SSRS, before and after each dosification period. Obtain a grade greater than zero in the C-SSRS. Do not sign the Informed Consent corresponding to the bioequivalence study. Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64600
Country
Mexico

12. IPD Sharing Statement

Learn more about this trial

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

We'll reach out to this number within 24 hrs